Barclays
DRMA icon

Barclays’s Dermata Therapeutics DRMA Stock Holding History

Barclays’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,402
Closed -$5.57K – 5141
2025
Q4 		$5.57K Buy
+2,402
New +$7.85K ﹤0.01% 4979

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays's DRMA Position: Q1 2026 in Review

Barclays sold out of Dermata Therapeutics (DRMA) in Q1 2026, closing a stake of 2,402 shares — an estimated $5.57K sold.

Barclays first reported a position in DRMA in Q4 2025 and held it in 1 quarter. The position peaked at $5.57K in Q4 2025. 7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

  • Barclays reported no remaining Dermata Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 2,402 Dermata Therapeutics shares in Q1 2026, an estimated $5.57K.
  • Barclays first reported a position in Dermata Therapeutics in Q4 2025 and held it in 1 quarter.
  • Barclays's Dermata Therapeutics position peaked at $5.57K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.